SCHEMBL3428498

SCHEMBL3428498

[CH2]CCC(C#N)CCCC

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
DNM1 Q05193 2/20 0.33
ALDH1A1 P00352 2/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3474884 0.93 TSHR (0.39) TSHRDNM1
SCHEMBL6050145 0.91 TSHR (0.37) TSHRDNM1
SCHEMBL3429100 0.88
SCHEMBL3677002 0.87 TSHR (0.50) TSHRDNM1ALDH1A1TDP1
SCHEMBL6050201 0.86 TSHR (0.37) TSHRDNM1
SCHEMBL3427139 0.83
SCHEMBL10155552 0.82 TSHR (0.46) TSHRDNM1
SCHEMBL3673710 0.82 TSHR (0.46) TSHRDNM1ALDH1A1TDP1
SCHEMBL29102703 0.82 TSHR (0.37) TSHRDNM1
SCHEMBL6050196 0.82 TSHR (0.37) TSHRDNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790897-B2 Graftable hindered amine light stabilizers CIBA SPECIALTY CHEMICALS CORP. (US) 2010-09-07 US disclosed
US-20090144915-A1 Graftable hindered amine light stabilizers MEIER HANS-RUDOLF 2009-06-11 US disclosed
US-7504510-B2 Graftable hindered amine light stabilizers CIBA SPECIALTY CHEMICALS CORP. (US) 2009-03-17 US disclosed
EP-1084710-B1 ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY ASTELLAS PHARMA INC (JP) 2006-10-18 EP disclosed
EP-1592664-B1 GRAFTABLE HINDERED AMINE LIGHT STABILIZERS CIBA SC HOLDING AG (CH) 2006-08-23 EP disclosed
US-20060173107-A1 Graftable hindered amine light stabilizers CIBA SPECIALTY CHEMICALS CORP. 2006-08-03 US disclosed
EP-1592664-A1 GRAFTABLE HINDERED AMINE LIGHT STABILIZERS Ciba SC Holding AG (CH) 2005-11-09 EP disclosed
WO-2004072035-A1 GRAFTABLE HINDERED AMINE LIGHT STABILIZERS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-08-26 WO disclosed
US-20040152659-A1 Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-08-05 US disclosed
US-6521656-B1 Contacting sperm with a pyrazolo(1,5-a)pyridine acrosomal reaction induction promoter then joining with ovum FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed
WO-1993025205-A1 PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-12-23 WO disclosed
US-5204346-A Cognition activators; analgesics; antidepressants; vasodilation; cardiovascular and urogential disorders; FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-04-20 US disclosed
EP-0497258-A2 Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-08-05 EP disclosed
EP-0467248-A2 Pyrazolopyridine compound and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-01-22 EP disclosed
EP-0003002-B1 USE OF AROMATIC-ALIPHATIC KETONES AS PHOTOINITIATORS, PHOTOPOLYMERISABLE SYSTEMS CONTAINING SUCH KETONES AND AROMATIC-ALIPHATIC KETONES CIBA-GEIGY AG (CH) 1984-06-13 EP disclosed
US-4321118-A Bis benzoyl sensitizers for photopolymerization or photo cross linking process and composition CIBA-GEIGY CORPORATION (US) 1982-03-23 US disclosed
US-4318791-A PHOTOPOLYMERIZABLE SYSTEM FOR INKS CIBA-GEIGY CORPORATION (US) 1982-03-09 US disclosed
US-4315807-A Sensitizers for photopolymerization CIBA-GEIGY CORPORATION (US) 1982-02-16 US disclosed
US-4308400-A AROMATIC HYDROXY KETONES CIBA-GEIGY A.G. (CH) 1981-12-29 US disclosed
EP-0003002-A2 Use of aromatic-aliphatic ketones as photoinitiators, photopolymerisable systems containing such ketones and aromatic-aliphatic ketones CIBA-GEIGY AG (CH) 1979-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152659-A1 Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist ADORA2A, ADORA1, ADORA2B TSHR 601/4885DNM1 1124/4885ALDH1A1 336/4885
US-20090144915-A1 Graftable hindered amine light stabilizers IDO1, MAOA, AOX1 TSHR 3638/4885DNM1 2028/4885ALDH1A1 29/4885
US-20060173107-A1 Graftable hindered amine light stabilizers IDO1, MAOA, TPH1 TSHR 3853/4885DNM1 1641/4885ALDH1A1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.